Increasing the efficacy of tumor cell vaccines by enhancing cross priming

Cancer Letters

Volumn 325, Issue 2, 2012, Pages 155-164

  Andersen, Brian M ^a   Ohlfest, John R ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alarmins; Dendritic cells; Immunotherapy

Indexed keywords

B7 ANTIGEN; CALRETICULIN; CD137 LIGAND; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; F ACTIN; GLYCOPROTEIN P 15095; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELACINE; OX40 LIGAND; OXYGEN; PHOSPHORYL LIPID A; RENIALE; TOLL LIKE RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CELL EXPANSION; CELL MATURATION; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EFFECTOR CELL; HUMAN; IMMUNOGENICITY; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STEADY STATE; TISSUE CULTURE; TUMOR IMMUNITY; VACCINE PRODUCTION;

EID: 84865630094     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.012     Document Type: Review

References (99)

1. W.B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases, Clin Orthop Relat Res (1893 and 1991) 3-11.
2. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 1994, 64:529-564.
3. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
4. Neller M.A., Lopez J.A., Schmidt C.W. Antigens for cancer immunotherapy. Semin Immunol. 2008, 20:286-295.
5. Sondak V.K., Sosman J.A. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol. 2003, 13:409-415.
6. Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., Schmitt E., Dannenberg T., Lehmacher W., von Wietersheim J., Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594-599.
7. May M., Brookman-May S., Hoschke B., Gilfrich C., Kendel F., Baxmann S., Wittke S., Kiessig S.T., Miller K., Johannsen M. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol. Immunother. 2010, 59:687-695.
8. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat. Rev. Immunol. 2010, 10:403-414.
9. Zinkernagel R.M. Restriction by H-2 gene complex of transfer of cell-mediated immunity to Listeria monocytogenes. Nature 1974, 251:230-233.
10. Kourilsky P., Claverie J.M. MHC-antigen interaction: what does the T cell receptor see?. Adv. Immunol. 1989, 45:107-193.
11. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 1976, 143:1283-1288.
12. Steinman R.M., Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973, 137:1142-1162.
13. Nussenzweig M.C., Steinman R.M. Contribution of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction. J. Exp. Med. 1980, 151:1196-1212.
14. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 1987, 165:302-319.
15. Jenkins M.K., Ashwell J.D., Schwartz R.H. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 1988, 140:3324-3330.
16. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001, 194:769-779.
17. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
18. + T cells. J. Immunol. 1999, 162:3256-3262.
19. Schmidt C.S., Mescher M.F. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 2002, 168:5521-5529.
20. Shu U., Kiniwa M., Wu C.Y., Maliszewski C., Vezzio N., Hakimi J., Gately M., Delespesse G. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 1995, 25:1125-1128.
21. Reddy A., Sapp M., Feldman M., Subklewe M., Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997, 90:3640-3646.
22. Bender A., Sapp M., Schuler G., Steinman R.M., Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 1996, 196:121-135.
23. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
24. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995, 182:389-400.
25. Pierre P., Turley S.J., Gatti E., Hull M., Meltzer J., Mirza A., Inaba K., Steinman R.M., Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997, 388:787-792.
26. Burgdorf S., Scholz C., Kautz A., Tampe R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 2008, 9:558-566.
27. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
28. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 1999, 5:1249-1255.
29. Shi Y., Zheng W., Rock K.L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 2000, 97:14590-14595.
30. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
31. Rock K.L., Latz E., Ontiveros F., Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 2010, 28:321-342.
32. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 2008, 36:1478-1481.
33. Kobata A., Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 2005, 83:429-439.
34. van Gisbergen K.P., Aarnoudse C.A., Meijer G.A., Geijtenbeek T.B., van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res. 2005, 65:5935-5944.
35. + T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
36. Barbalat R., Ewald S.E., Mouchess M.L., Barton G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 2011, 29:185-214.
37. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
38. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29:352-361.
39. Segura E., Valladeau-Guilemond J., Donnadieu M.H., Sastre-Garau X., Soumelis V., Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J. Exp. Med. 2012, 209:653-660.
40. Lindstedt M., Lundberg K., Borrebaeck C.A. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J. Immunol. 2005, 175:4839-4846.
41. + dendritic cells. J. Exp. Med. 2010, 207:1261-1271.
42. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207:1247-1260.
43. Flacher V., Bouschbacher M., Verronese E., Massacrier C., Sisirak V., Berthier-Vergnes O., de Saint-Vis B., Caux C., Dezutter-Dambuyant C., Lebecque S., Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 2006, 177:7959-7967.
44. van de Ven R., van den Hout M.F., Lindenberg J.J., Sluijter B.J., van Leeuwen P.A., Lougheed S.M., Meijer S., van den Tol M.P., Scheper R.J., de Gruijl T.D. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood 2011, 118:2502-2510.
45. Itano A.A., McSorley S.J., Reinhardt R.L., Ehst B.D., Ingulli E., Rudensky A.Y., Jenkins M.K. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19:47-57.
46. Allenspach E.J., Lemos M.P., Porrett P.M., Turka L.A., Laufer T.M. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity 2008, 29:795-806.
47. + T cell activation. Immunity 2007, 27:625-634.
48. Mempel T.R., Henrickson S.E., Von Andrian U.H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004, 427:154-159.
49. Hangalapura B.N., Oosterhoff D., Gupta T., de Groot J., Wijnands P.G., van Beusechem V.W., den Haan J., Tüting T., van den Eertwegh A.J., Curiel D.T., Scheper R.J., de Gruijl T.D. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine 2011, 29:2313-2321.
50. + dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 2005, 202:1063-1073.
51. Munn D.H., Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 2006, 213:146-158.
52. + T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 2011, 29:984-993.
53. Vezys V., Yates A., Casey K.A., Lanier G., Ahmed R., Antia R., Masopust D. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009, 457:196-199.
54. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 2004, 10:187-192.
55. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
56. Perez S.A., von Hofe E., Kallinteris N.L., Gritzapis A.D., Peoples G.E., Papamichail M., Baxevanis C.N. A new era in anticancer peptide vaccines. Cancer 2010, 116:2071-2080.
57. Kanduc D. "Self-nonself" peptides in the design of vaccines. Curr. Pharm. Des. 2009, 15:3283-3289.
58. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., Hundal J., Wendl M.C., Demeter R., Wylie T., Allison J.P., Smyth M.J., Old L.J., Mardis E.R., Schreiber R.D. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
59. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., Gilbert M.R., Herndon JE 2nd, McLendon R.E., Mitchell D.A., Reardon D.A., Sawaya R., Schmittling R.J., Shi W., Vredenburgh J.J., Bigner D.D. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:4722-4729.
60. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
61. Pellegatta S., Poliani P.L., Corno D., Menghi F., Ghielmetti F., Suarez-Merino B., Caldera V., Nava S., Ravanini M., Facchetti F., Bruzzone M.G., Finocchiaro G. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006, 66:10247-10252.
62. Pion S., Christianson G.J., Fontaine P., Roopenian D.C., Perreault C. Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Blood 1999, 93:952-962.
63. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26:638-648.
64. Olin M.R., Andersen B.M., Litterman A.J., Grogan P.T., Sarver A.L., Robertson P.T., Liang X., Chen W., Parney I.F., Hunt M.A., Blazar B.R., Ohlfest J.R. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res. 2011, 71:6583-6589.
65. Olin M.R., Andersen B.M., Zellmer D.M., Grogan P.T., Popescu F.E., Xiong Z., Forster C.L., Seiler C., SantaCruz K.S., Chen W., Blazar B.R., Ohlfest J.R. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res. 2010, 16:4800-4808.
66. Twitty C.G., Jensen S.M., Hu H.M., Fox B.A. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin. Cancer Res. 2011, 17:6467-6481.
67. Li Y., Wang L.X., Yang G., Hao F., Urba W.J., Hu H.M. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008, 68:6889-6895.
68. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J.L., Schlemmer F., Tasdemir E., Uhl M., Génin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., André F., Lidereau R., McLaughlin N.M., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
69. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G., Rello-Varona S., Tailler M., Menger L., Vacchelli E., Galluzzi L., Ghiringhelli F., di Virgilio F., Zitvogel L., Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
70. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 2000, 191:423-434.
71. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
72. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L.L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M.K., Fitzgerald K.A., Latz E., Kiener P.A., Coyle A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8:487-496.
73. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
74. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., Choe K.H., Strassheim D., Pitts T.M., Tracey K.J., Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol. 2003, 284:C870-C879.
75. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
76. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
77. Tsan M.F. Heat shock proteins and high mobility group box 1 protein lack cytokine function. J. Leukoc. Biol. 2011, 89:847-853.
78. Tsan M.F., Gao B. Heat shock proteins and immune system. J. Leukoc. Biol. 2009, 85:905-910.
79. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., Germain R.N. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 2000, 191:1957-1964.
80. Imai T., Kato Y., Kajiwara C., Mizukami S., Ishige I., Ichiyanagi T., Hikida M., Wang J.Y., Udono H. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc. Natl. Acad. Sci. USA 2011, 108:16363-16368.
81. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845.
82. See A.P., Pradilla G., Yang I., Han S., Parsa A.T., Lim M. Heat shock protein-peptide complex in the treatment of glioblastoma. Exp. Rev. Vaccines 2011, 10:721-731.
83. Eton O., Ross M.I., East M.J., Mansfield P.F., Papadopoulos N., Ellerhorst J.A., Bedikian A.Y., Lee J.E. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J. Transl. Med. 2010, 8:9.
84. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
85. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martínez D., Hernanz-Falcón P., Rosewell I., Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
86. Ahrens S., Zelenay S., Sancho D., Hanč P., Kjær S., Feest C., Fletcher G., Durkin C., Postigo A., Skehel M., Batista F., Thompson B., Way M., Reis e Sousa C., Schulz O. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012, 36:635-645.
87. Zhang J.G., Czabotar P.E., Policheni A.N., Caminschi I., Wan S.S., Kitsoulis S., Tullett K.M., Robin A.Y., Brammananth R., van Delft M.F., Lu J., O'Reilly L.A., Josefsson E.C., Kile B.T., Chin W.J., Mintern J.D., Olshina M.A., Wong W., Baum J., Wright M.D., Huang D.C., Mohandas N., Coppel R.L., Colman P.M., Nicola N.A., Shortman K., Lahoud M.H. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 2012, 36:646-657.
88. + myeloid dendritic cells. Blood 2012, 119:2284-2292.
89. Idoyaga J., Lubkin A., Fiorese C., Lahoud M.H., Caminschi I., Huang Y., Rodriguez A., Clausen B.E., Park C.G., Trumpfheller C., Steinman R.M. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. USA 2011, 108:2384-2389.
90. Zelenay S., Keller A.M., Whitney P.G., Schraml B.U., Deddouche S., Rogers N.C., Schulz O., Sancho D., Reis E., Sousa C. The DC receptor DNGR-1 controls endocytic handling of dead cell antigens to favor cross-priming of CTL in virus-infected mice. J. Clin. Invest. 2012, 122:1615-1627.
91. Kerrigan A.M., Brown G.D. Syk-coupled C-type lectins in immunity. Trends Immunol. 2011, 32:151-156.
92. Rothfuchs A.G., Bafica A., Feng C.G., Egen J.G., Williams D.L., Brown G.D., Sher A. Dectin-1 interaction with Mycobacterium tuberculosis leads to enhanced IL-12p40 production by splenic dendritic cells. J. Immunol. 2007, 179:3463-3471.
93. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
94. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 2000, 191:411-416.
95. Hoves S., Sutton V.R., Haynes N.M., Hawkins E.D., Fernández Ruiz D., Baschuk N., Sedelies K.A., Schnurr M., Stagg J., Andrews D.M., Villadangos J.A., Trapani J.A. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J. Immunol. 2011, 187:1166-1175.
96. Kastenmuller K., Wille-Reece U., Lindsay R.W., Trager L.R., Darrah P.A., Flynn B.J., Becker M.R., Udey M.C., Clausen B.E., Igyarto B.Z., Kaplan D.H., Kastenmüller W., Germain R.N., Seder R.A. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 2011, 121:1782-1796.
97. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Métivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
98. Ogden C.A., deCathelineau A., Hoffmann P.R., Bratton D., Ghebrehiwet B., Fadok V.A., Henson P.M. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 2001, 194:781-795.
99. Bondanza A., Zimmermann V.S., Rovere-Querini P., Turnay J., Dumitriu I.E., Stach C.M., Voll R.E., Gaipl U.S., Bertling W., Pöschl E., Kalden J.R., Manfredi A.A., Herrmann M. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J. Exp. Med. 2004, 200:1157-1165.